Movement Disorders

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in movement disorders in 2024.

Mind Moments®, a podcast from NeurologyLive®, brings you a review of 2024, with insights from Daniel Ontaneda, MD, PhD; Ian Kremer; Andy Berkowski, MD, PhD; Sameea Husain-Wilson, DO; Jonathan Parker, MD, PhD; and Lawrence Robinson, MD. [LISTEN TIME: 25 minutes]

As part of NeurologyLive®'s Year in Review, we've compiled the top coverage stories from 2024 across a variety of different neurological conferences the team either attended or covered virtually.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2024.

Since the Syn-One Test only needs a small punch skin biopsy that can be collected in an office setting, the clinical utility can be enhanced to offer more geographically convenient access for patients earlier in the disease.

Although the primary goal was not met, prasinezumab demonstrated encouraging effects on secondary and exploratory measures, such as time to worsening motor function, Clinical Global Impression of Change, MDS-UPDRS motor scores.

The chief executive officer and cofounder of Amprion provided clinical insight on the novelty behind the company’s synuclein seed amplification assay and how it may better differentiate synucleinopathies diseases like MSA. [WATCH TIME: 8 minutes]

The FDA has agreed that a scale used in ongoing phase 1/2 clinical trials could potentially serve as an intermediate clinical end point for accelerated approval pathway for uniQure’s investigational gene therapy AMT-130.

AbbVie recently announced that it is on track to submit the new drug application for its investigational Parkinson disease agent tavapadon to the FDA in 2025.

BIIB122 is a selective, central nervous system-penetrant small molecule that could potentially improve lysosomal dysfunction among patients with LRRK2-associated Parkinson disease.

Factors like education level, hypertension, diabetes, and depression did not significantly predict epilepsy risk in patients with dementia.

Perspective from neurologists on the current and future applications for artificial intelligence across a bevy of neurologic conditions.

Catch up on any of the neurology news headlines you may have missed over the course of November 2024, compiled all into one place by the NeurologyLive® team.

The Association of Movement Disorder Advanced Practice Providers has launched its Certification of Movement & Related Disorder Specialist (CMRD) for advanced practice providers.

To date, BT-267 shows strong potential as a best-in-class LRRK2 inhibitor for Parkinson disease, with a superior safety profile, excellent pharmacokinetics, and innovative development leveraging advanced technologies and biomarker modeling.

Neurology News Network. for the week ending November 30, 2024. [WATCH TIME: 4 minutes]

In a 76-patient cohort, HL192 was safe and well tolerated across 5 observed dose levels, with a treatment-emergent adverse event incidence that mirrored placebo.

Hearing loss, as defined by objective audiograms, was associated with an additional risk of developing PD later in life in a dose-dependent manner.

Amanda Hare, DNP, a doctor of nursing practice specialized in movement disorders, gave comments on the innovation behind the StrivePD app and how it can revolutionize personalized treatment management for patients with Parkinson disease.

Neurology News Network. for the week ending November 23, 2024. [WATCH TIME: 4 minutes]

Findings from a recently published study suggest patients with Parkinson disease can reduce postural sway as efficiently as neurologically healthy patients when performing horizontal saccades.

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

The phase 2 DIMENSION study results showed that SAGE-71 was well-tolerated but did not meet its primary end point, leading to Sage Therapeutics’ decision to discontinue its development.

At week 10, investigators observed no differences between triheptanoin and placebo on the frequency of movement disorder events in patients with Glut1 deficiency disorder.

The global, placebo-controlled, 12-week study aims to enroll 330 participants and expects topline results in the first half of 2026.